Valuation: Interpace Biosciences, Inc.

Market Cap 42.79M 37.61M 35.01M 32.16M 60.38M 4.1B 61.18M 416M 163M 2.03B 161M 157M 7B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 41.46M 36.45M 33.93M 31.16M 58.52M 3.98B 59.29M 403M 158M 1.96B 156M 152M 6.79B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
14.74%
Yield 2024 *
-
Yield 2025 -
1 day+5.79%
1 week+3.66%
Current month-5.24%
1 month-6.39%
3 months-20.13%
6 months-11.74%
Current year+25.56%
1 week 1.34
Extreme 1.34
1.54
1 month 1.34
Extreme 1.34
1.8
Current year 1.03
Extreme 1.03
2.4
1 year 0.77
Extreme 0.77
2.4
3 years 0.44
Extreme 0.4433
3.54
5 years 0.44
Extreme 0.4433
10.33
10 years 0.44
Extreme 0.4433
198
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap.
20/01/26
Ampersand Management LLC
ConversionCompany 13,861,386 313.0013%
20/01/26
1315 Capital LLC
ConversionCompany 9,405,941 212.3938%
01/02/24 Free

Chief Financial Officer

10,000 0.2314%
Change 5-day change 1-year change 3-year change Capi.($)
+5.79%+3.66%+71.60%-20.79% 40.44M
-1.51%-1.75%+85.77%+469.35% 37.52B
+1.48%+7.00%+13.67%+39.40% 24.34B
+0.89%-0.46%-23.53%-39.21% 7.33B
-0.10%+1.37%+7.14%+87.53% 4.84B
+3.87%+8.28%+18.76%+51.22% 3.05B
-5.40%-7.72%+108.90%-20.17% 1.81B
+1.81%+0.27%-12.74%-62.95% 1.78B
+2.44%-0.18%-24.16%+737.34% 1.75B
+7.34%-0.18%+14.63%+4.49% 1.74B
Average +1.66%-1.53%+26.00%+124.62% 8.42B
Weighted average by Cap. +0.09%+0.00%+43.11%+237.68%

Financials

2024 2025
Net sales 46.93M 41.25M 38.4M 35.27M 66.22M 4.5B 67.09M 456M 178M 2.22B 176M 172M 7.68B 38.73M 34.05M 31.69M 29.11M 54.65M 3.71B 55.37M 377M 147M 1.83B 145M 142M 6.34B
Net income 6.7M 5.89M 5.48M 5.04M 9.46M 643M 9.58M 65.19M 25.46M 317M 25.16M 24.62M 1.1B 24.58M 21.6M 20.11M 18.47M 34.68M 2.36B 35.14M 239M 93.36M 1.16B 92.25M 90.26M 4.02B
Net Debt 4.4M 3.86M 3.6M 3.3M 6.2M 421M 6.28M 42.75M 16.7M 208M 16.5M 16.14M 719M -1.32M -1.16M -1.08M -994K -1.87M -127M -1.89M -12.86M -5.02M -62.6M -4.96M -4.86M -216M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
27/07/26 $1.545 +5.79% 320
24/07/26 $1.460 +0.69% 4,002
23/07/26 $1.450 -3.97% 2,536
22/07/26 $1.510 +0.37% 4,632
21/07/26 $1.504 +0.97% 1,217

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG Stock